Cancer treatment often depends on chemotherapy to destroy or slow the growth of cancer cells. But chemotherapy drugs do not act only on the tumour. They can also reach healthy tissues, which is one reason treatment can cause significant side effects. Some drugs are also cleared from the body quickly, and tumour cells can develop resistance over time.
These limitations have led researchers to study nano drug delivery in cancer. Nano sized carriers can help protect anti cancer drugs, extend their circulation time, and improve drug accumulation in tumour tissue.
The focus is to deliver treatment more effectively while reducing unnecessary exposure to healthy cells. The same formulation principle is also relevant to supportive supplementation. Let’s discuss them in detail.
Key Highlights
- Nano drug delivery in cancer uses nanocarriers to improve how anti cancer drugs are protected, circulated, released, and delivered to tumour tissue.
- Passive targeting and active targeting are the two main approaches used to improve nanoparticle delivery to cancer cells and tumour tissue.
- Common nano drug delivery systems include liposomes, polymeric nanoparticles, micelles, solid lipid nanoparticles, silica nanoparticles, and inorganic nanoparticles.
- Key benefits of nano drug delivery include better drug solubility, improved stability, longer circulation time, controlled release, and potentially better tumour accumulation.
- New trends in cancer nanomedicine include stimuli responsive nanoparticles, nano immunotherapy, RNA delivery, theranostics, biomimetic carriers, and AI guided nanomedicine.
What Is Nano Drug Delivery in Cancer?
Nano drug delivery in cancer uses tiny carriers, usually 1 to 100 nanometres in size, to transport therapeutic compounds through the body and influence where, when, or how those compounds are released.
Nanoparticles used in cancer research are commonly created according to their:
- size,
- surface properties,
- material,
- drug loading capacity,
- circulation time,
- and release behaviour.
The body does not treat every particle in the same way. For example, very small particles may be filtered rapidly by the kidneys, while larger particles may be recognised and cleared by cells of the immune system. Surface modifications can also influence how long a nanoparticle remains in circulation.
Nanotechnology is not useful only because the particle is small; rather, it changes the behaviour of the payload in a clinically meaningful way.
For a deeper explanation of how nano sized formulations are created and how they influence solubility and bioavailability in nutraceuticals, see our guide to nano encapsulation technology in nutraceuticals.
How Does Nano Drug Delivery Happen in Cancer Care?
Nano drug delivery begins by placing an anti cancer drug inside or onto a nanocarrier. The carrier protects the drug as it moves through the bloodstream and can change how long the drug stays in circulation, where it accumulates, and when it is released.
Two main targeting approaches in cancer care include:
- Passive targeting: Some nanoparticles can accumulate in tumour tissue because tumour blood vessels are often abnormal and more permeable than healthy vessels. This is commonly linked to the enhanced permeability and retention (EPR) effect, although its strength varies between tumour types and patients.
- Active targeting: Nanocarriers can be coated with molecules such as antibodies, peptides, or folate that recognise specific receptors found at higher levels on certain cancer cells. This can improve interaction and uptake by those cells.
Some advanced nanocarriers are also designed to release the drug in response to conditions such as acidity, enzymes, or other features of the tumour environment.
Also Read: How to Support Cancer Fatigue Naturally
Types of Nano Drug Delivery Systems
Different nanocarriers are used in cancer therapy because each has different properties for carrying and releasing drugs.
| Nano Delivery System | How It Works |
|---|---|
| Liposomes | Lipid based vesicles that can carry water soluble or fat soluble drugs and help protect them during circulation. |
| Polymeric nanoparticles | Biodegradable polymer based carriers that can be designed for controlled or sustained drug release. |
| Polymeric micelles | Have a water friendly outer layer and a hydrophobic core, making them useful for poorly water soluble drugs. |
| Solid lipid nanoparticles | Use solid lipids to carry active compounds and can improve stability and controlled release. |
| Mesoporous silica nanoparticles | Contain tiny pores that can hold drugs and can be modified for controlled release or targeting. |
| Gold and other inorganic nanoparticles | Studied for drug delivery, imaging and treatments such as photothermal therapy. |
Liposomes, polymeric nanoparticles, micelles, lipid based systems, silica nanoparticles and inorganic nanoparticles are among the major nanocarriers studied in cancer therapy. The choice depends on factors such as drug solubility, stability, release pattern, and the intended biological target.
Advantages of Nano Drug Delivery Systems for Cancer
| Problem in Conventional Delivery | What Nano Delivery May Change |
|---|---|
| Poor drug solubility | Encapsulation can improve dispersion |
| Rapid drug degradation | Carrier may protect the payload |
| Short circulation time | Surface engineering may prolong circulation |
| High exposure to healthy tissue | Distribution may be altered |
| Poor tumour accumulation | Some carriers may improve local accumulation |
| Limited cellular uptake | Targeting ligands may increase receptor mediated uptake |
| Drug efflux resistance | Nanoparticles may enter cells through alternative pathways |
| Need for multiple drugs | Some carriers allow co delivery |
| Premature drug release | Stimuli responsive systems may control release |
The benefit of nano formulation in supplements is primarily related to how the ingredient is protected, absorbed and delivered.
For example, chitosan based nanoparticles respond to tumor acidity. They release drugs precisely where needed. This boosts outcomes and lowers harmful effects.
Current Trends and Innovations in Nano Medicine for Cancer Care
Cancer nanomedicine is moving beyond basic drug delivery, with current research focused on more precise and responsive treatment approaches.
- Stimuli-responsive nanoparticles: Designed to release drugs in response to tumour conditions such as acidic pH, enzymes or external triggers like light and ultrasound.
- Nano-immunotherapy: Uses nanocarriers to improve the delivery of immune active agents within the tumour environment.
- RNA delivery: Lipid and polymer based nanoparticles are being studied to protect and deliver mRNA, siRNA, and other genetic therapies.
- Theranostic systems: Combine drug delivery with imaging or diagnostic functions in a single nano platform.
- Biomimetic nanocarriers: Use cell derived materials to improve circulation and reduce rapid immune clearance.
- AI-guided nanomedicine: An emerging area using AI to optimise nanoparticle design, targeting and drug delivery.
Most of these approaches are still under research, with tumour variability, safety, manufacturing and clinical translation remaining major challenges.
How Nano-Supplements Help in Cancer Care
Nano supplements may support cancer care by improving the absorption of key plant compounds, supporting the body’s natural defences, helping manage inflammation, and supporting healthy cell recovery.
One example is ZeroHarm’s nano formulated cancer care tablet, Holo Oncolis is formulated with nano curcuminoids and peptides, triterpenoid saponins, bacosides A1, A2 and A3, and pectin. The nano formulation may help improve the delivery and bioavailability of active compounds such as curcuminoids, which are otherwise poorly absorbed.
Holo Oncolis may be considered by people undergoing cancer treatment who need additional nutritional support, patients recovering from chemotherapy or radiation, and cancer survivors focused on rebuilding strength and overall recovery.
It is designed to complement prescribed cancer treatment and should be discussed with an oncologist before use.
Are Nano-Supplements Safe During Cancer Treatment?
Nano formulation can improve the delivery of certain ingredients, but better absorption can also make potential interactions more relevant.
Some herbs, antioxidants and dietary supplements can change how cancer drugs are absorbed, metabolised or cleared from the body. So, before using a cancer support supplement, check:
- whether it can interact with your current treatment,
- whether the dose is appropriate,
- whether you are taking other supplements with similar ingredients,
- and whether the product is intended for supportive use rather than cancer treatment.
Conclusion
Nano drug delivery is opening new possibilities in cancer care by improving how anti cancer drugs are protected, circulated, and delivered to tumour tissue. It is being studied for challenges such as poor drug solubility, short circulation time, limited tumour delivery, and drug resistance.
For supportive care, nano supplements may help improve the solubility, stability, and bioavailability of plant based compounds such as curcuminoids, making them more available to the body.
It is important to look at the ingredients, formulation, evidence, and how well the product fits alongside the patient’s treatment plan, and to stay well informed for better health.
Products such as Holo Oncolis may be considered as additional nutritional support during cancer care, with guidance from the treating oncologist.
